Nuevocor Strengthens Leadership with New Board Member
Nuevocor, a biotechnology company headquartered in Singapore, has announced the appointment of Dr. Thierry Abribat to its Board of Directors. This strategic move marks a significant milestone for the company as it advances its mission to develop innovative therapies for cardiac conditions influenced by mechanobiology.
Dr. Thierry Abribat's Impressive Background
Dr. Thierry Abribat brings a wealth of experience as a seasoned biotech executive and entrepreneur. He has successfully founded and led three biotechnology companies, focusing on developing transformative therapies to address critical medical needs. Notably, he facilitated the impressive $1 billion acquisition of Amolyt Pharma by AstraZeneca, highlighting his capacity to elevate biotech firms for substantial exits.
Impactful Contributions to Biotechnology
Beyond the acquisition of Amolyt Pharma, Dr. Abribat's entrepreneurial journey includes leading Alizé Pharma, which was acquired by Millendo Therapeutics in 2017, and Alizé Pharma 2, brought into the fold by Jazz Pharmaceuticals in 2016. His extensive leadership experience spans drug development, business operations, and general management roles, including his tenure as Chief Scientific Officer at Theratechnologies and Chief Operating Officer at OPi SA.
Vision for Nuevocor
Expressing excitement about joining the company, Dr. Abribat stated, "I am thrilled to be part of Nuevocor at this crucial juncture. Their innovative approach to mechanobiology holds promise for transforming care for patients afflicted by severe genetic cardiomyopathies. I look forward to contributing to this important scientific journey as they prepare to bring cutting-edge therapies to clinical settings."
Welcoming Dr. Abribat
Dr. Andreas Wallnöfer, Chairman of the Board at Nuevocor, emphasized the company's honor in welcoming Dr. Abribat. He noted, "Thierry is an outstanding entrepreneur with a notable history of scaling biotech companies and making scientific advancements a reality through successful therapeutics. His insights and experience will be essential as we evolve into a clinical-stage enterprise and broaden our footprint in international markets, particularly in Europe."
Innovative Therapeutics: NVC-001
NVC-001 is a pioneering AAV-based gene therapy designed to tackle LMNA-related dilated cardiomyopathy. This condition, characterized by rapid progression to severe heart failure, presents significant risks, including sudden cardiac death. NVC-001 aims to restore nuclear envelope integrity, a critical component affected in LMNA DCM, thereby addressing the underlying disease mechanisms. Early studies have demonstrated promising results in enhancing survival and cardiac performance.
Future Clinical Trials
Nuevocor is preparing to commence a Phase 1/2 clinical trial for NVC-001, targeting early 2026 for initiation. Trials will be conducted across sites in the U.S. and Europe, marking a significant step in bringing this vital therapy to patients in need.
About Nuevocor
Nuevocor specializes in developing cutting-edge therapies for genetic cardiomyopathies that stem from mechanobiological irregularities. With its headquarters in Singapore and offices in the U.S. and Europe, Nuevocor is committed to addressing diseases that traditional gene replacement therapies cannot adequately treat. Their innovative PrOSIA mechanobiology platform goes beyond merely replacing dysfunctional genes; it targets the underlying biological issues shared among various cardiomyopathies, promising hope for patients without effective treatment options.
Frequently Asked Questions
What was the recent appointment announced by Nuevocor?
Nuevocor announced the appointment of Dr. Thierry Abribat to its Board of Directors, enhancing its leadership team.
What is Dr. Thierry Abribat's background?
Dr. Abribat is a well-respected biotech executive with experience in founding and managing biotech companies, and he recently led a $1 billion acquisition of Amolyt Pharma.
What is NVC-001?
NVC-001 is a groundbreaking AAV-based gene therapy aimed at treating LMNA-related dilated cardiomyopathy, focusing on restoring nuclear envelope integrity.
When does Nuevocor plan to initiate clinical trials for NVC-001?
Nuevocor aims to begin a Phase 1/2 clinical trial for NVC-001 in early 2026 at various sites in the U.S. and Europe.
What is the mission of Nuevocor?
Nuevocor focuses on developing novel therapies for genetic cardiomyopathies driven by mechanobiological factors, targeting root causes of disease rather than just symptoms.
